Compare AIMD & PIII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIMD | PIII |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 10.8M |
| IPO Year | N/A | N/A |
| Metric | AIMD | PIII |
|---|---|---|
| Price | $1.46 | $2.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $16.25 |
| AVG Volume (30 Days) | 41.2K | ★ 75.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $14.85 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.44 | $0.15 |
| 52 Week High | $4.50 | $11.30 |
| Indicator | AIMD | PIII |
|---|---|---|
| Relative Strength Index (RSI) | 43.94 | 60.01 |
| Support Level | $1.26 | $1.52 |
| Resistance Level | $1.79 | $3.85 |
| Average True Range (ATR) | 0.13 | 0.43 |
| MACD | 0.01 | 0.16 |
| Stochastic Oscillator | 37.22 | 52.91 |
Ainos Inc is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. It combines AI and Nose, redefining machine perception for the sensory age.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.